An ongoing Phase 1 trial of icodec (ClinicalTrials.gov registration no. NCT06288412) will partially address these limitations by providing additional safety data for icodec during and after exercise and prolonged fasting in insulin-experienced individuals with type 2 diabetes. Here, INS is linked to type 2 diabetes mellitus.